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Through a twist of fate the most common form of HIV-1, as defined by entry phenotype, was not
appreciated until recently. The entry phenotype is closely linked to the target cell and thus to
virus–host interactions and pathogenesis. The most abundant form of HIV-1 uses CCR5 as the
coreceptor and requires a high density of CD4 for efficient entry, defining its target cell as the
CD4+memory T cell. This is the transmitted form of the virus, the form that is found in the blood,
and the form that rebounds from the latent reservoir.WhenCD4+/CCR5+T cells become limiting
the virus evolves to use alternative target cells to support viral replication. In the CNS, the virus
can evolve to use a cell that displays only a low density of CD4, while maintaining the use of CCR5
as the coreceptor. When this evolutionary variant evolves, it must be sustaining its replication in
either macrophages or microglial cells, which display only a low density of CD4 relative to that on
T cells. In the blood and lymphoid system, themajor switch late in disease is fromTcells expressing
CD4andCCR5 toT cells expressingCD4andCXCR4,with a change in coreceptor specificity. Thus
the virus responds in two different ways to different environments when its preferred target cell
becomes limiting.
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1 INTRODUCTION
It is a special treat to write a review for the Society of Leukocyte Biol-
ogy. There is a long history of viruses giving insights into fundamental
cell processes. For example, one of us (R.S.) was present many years
ago at a Cold Spring Harbor Retroviruses Meeting where an experi-
ment was presented of annealing adenoviral mRNA to viral DNA with
the product analyzed by EM; there were big loops in the DNA strand
giving birth to the idea of splicing. The story we have to tell today is
not as grandiose, but it is of fundamental importance to understand-
ing HIV-1 replication and pathogenesis. Ironically, it is a story that got
off track 30 years ago and we have taken up the task of setting the
story, and the biology, straight. In this review, we will explain why, until
recently, there has been no name for themost abundant form of HIV-1
as defined by its cell entry phenotype. This is because the nature of the
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“normal” entry phenotype is oftenmisunderstood. In clarifying thenor-
mal entry phenotype we will also discuss why macrophage-tropic (M-
tropic) HIV-1, which was previously assumed to be the predominant
formof the virus, is actually rare. Aswehave come to understand these
different entry phenotypes, we have come to realize that the virus is
telling us something about the cells in its local environment. Specifi-
cally, the virus is telling us about the cellular surface proteins on those
local cells: CD4 (the primary receptor for the virus), CCR5 (the usual
coreceptor), and CXCR4 (an alternative coreceptor). Importantly, the
way the virus interacts with each of these proteins changes over the
course of infection in a way that defines changing target cells.
Our focus in this review is to examine the viral surface protein,
known as the Envelope or Env protein. It is the only viral protein on
the surface of the lipid membrane (the “envelope”) of the virus par-
ticle (reviewed in Ref. 1) and is anchored there as a transmembrane
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protein. The Env protein is synthesized on the rough ER and is a type 1
integral membrane protein. There is an N-terminal signal peptide that
is cleaved off leaving a 160-kDa precursor protein as the initial trans-
lation product; this protein is heavily glycosylated giving rise to the
alternative name of gp160 (i.e., glycoprotein of 160 kDa). The gp160
formof the protein trimerizes and is transported through theER/Golgi.
In theGolgi, the individual subunits of the trimer are cleaved by a furin-
like protease to give rise to two proteins, gp120 and gp41, that stay
together noncovalently. gp120 is completely outside of the virus parti-
cle and is called the Surface or SU protein. It is responsible for recep-
tor and coreceptor binding. gp41 remains as a transmembrane protein
giving rise to its name, TM, with an extracellular domain, a transmem-
brane domain, and a cytoplasmic domain; the gp41 protein mediates
fusion between the viral and hostmembranes during entry. Like gp160,
the gp120/gp41 complex remains as a trimer first on the surface of the
host cell and then as part of the budded virus particle. The heavy gly-
cosylation of Env results in one-half of the molecular mass of gp120
being carbohydrate,2–4 with the role of these carbohydrates being to
shield the Env protein from becoming the target of host-neutralizing
antibodies that would otherwise use the surface of the protein as neu-
tralization epitopes.5–7
1.1 The old view of HIV-1: HIV-1 can be X4 T
cell-tropic or R5M-tropic
All viruses infect target cells based on the presence of a receptor on
the cell surface. For HIV-1, the receptor was defined early on based
on the observation that an antibody to the cell surface protein CD4
could blockHIV-1 infection.8,9 CD4 is an accessory protein on T helper
cells that helps to stabilize the binding of the T cell receptor to peptide-
presenting MHC Class II proteins on the surface of antigen present-
ing cells. This was the initial hint that CD4+ T helper cells are the tar-
get of HIV-1 infection, an idea that was subsequently supported by
numerous lines of evidence including the fact that these cells are lost
during the course of infection (see, e.g., Ref. 10) and the fact that the
HIV-1 Env protein binds to11 and has a high affinity for CD4.12,13 How-
ever, even early on it was clear that not all HIV-1 isolates could enter
all CD4-expressing cells,14 but the initial assumptions in interpreting
these early infection experiments generatedmisconceptions about the
nature of these restrictions in HIV-1 entry phenotypes.
Misconceptions in our understanding of HIV-1 entry phenotypes
remain prevalent and can largely be traced back to the fact that we
virologists are usually virologists first and cell biologists a distant sec-
ond (with some notable exceptions). As a result, most virology stud-
ies do not use the primary cells that viruses infect in vivo. The first
shortcut we take is to figure out what continuous cell line the virus
will grow in, hopefully similar to the target cell in vivo, but we must all
acknowledge that transformed cell lines do not always recapitulate a
phenomenon that exists in a whole organism. However, when you mix
100 virus particles with cells in culture and a week later you have 10
million particles and dead cells you usually feel that important parts of
the biology of viral replication are in place. Such cells were found in the
form of cell lines that had been derived from CD4+ T cell leukemias.
These cell lines in combination with viral isolates capable of growing
in these cells were important tools for developing much of our initial
understanding of HIV-1. This was enough to allow the development
of diagnostic tests, cloning of the viral genome followed by the deter-
mination of its entire genomic sequence, the generation of infectious
virus from cloned DNA to allow mutagenesis, and the definition of all
the viral genes and their gene products. Given the relatively small size
of theHIV-1 genome (around10,000bases), all of this happenedwithin
just a few years (although our knowledge of how the virus interacts
with host cell proteins is still incomplete). As these tools and reagents
became available, it was possible to develop antiviral drugs, initially to
the viral DNApolymerase reverse transcriptase and the viral protease,
andmore recently to the viral integrase, accomplishments that are dra-
matically changing the nature of the HIV-1 epidemic. All good.
Like all good mystery stories, there is an additional narrative em-
bedded in this truly amazing history. The early isolates of HIV-1 came
from people who were diagnosed with immunodeficiency. One thing
that oftenhappens as people progress to immunodeficiency is the virus
undergoes a “coreceptor switch” from using CCR5 to using CXCR4 as
the coreceptor.15–17 At the time the first isolates were made nothing
was known about the coreceptor so the fact that the virus existed as a
mixture of entry phenotypes could not be appreciated. Also, unknown
at the time of these early experiments, the transformed T cell lines that
were being used expressed CD4 and CXCR4, but not CCR518 (this is
true of most CD4+ transformed T cell lines). All of this adds up to the
fact that someof our early “insights” intoHIV-1entry phenotypeswere
basedonCXCR4-using viruseswhichwenowknoware anunusual sub-
set of HIV-1 variants that primarily emerge late in disease.
There was great positive reinforcement in using viral isolates from
late in infection and transformed T cell lines because they revealed dis-
tinct viral phenotypes. One example is in a phenomenon termed syn-
cytium formation. When infected cells express Env on their surface
they can behave like a virus particle and can fuse with an adjacent cell
that is expressing the CD4 receptor (and appropriate coreceptor) to
formmulticell syncytia, sometimes swelling with water to look like dis-
tended balloons. Because of this behavior in CD4+ T cell lines, some
of the earliest HIV-1 isolates were given two names: one descriptive,
syncytium-inducing (SI), and onemechanistic, T cell-tropic (for the abil-
ity to grow in a T cell line). By default, those viruses that did not form
syncytia were non-syncytium inducing (NSI), and since they apparently
did not grow in a T cell line, they were not T cell-tropic. However, in
hindsight these conclusions and designations are limited by proper-
ties of the T cell lines that could not have been appreciated at that
time. This early classification of HIV-1 as one of two types persists as
a significant misunderstanding to this day, and even some of the erro-
neous conclusions about viral populations persist from the use of these
T cell lines. The first important clue that we were on the wrong track
was that all of these viruses grew in PBMCs (think CD4+ T cells) but
given the framework of available information the failure to grow in a
T cell line was viewed as a limiting feature of the NSI viruses (making
them less pathogenic) and not a defective feature of the cell line that
prevented it from recapitulating real CD4+ T cells (i.e., the absence of
CCR5 expression).
In this world of T cell-tropic/SI versus NSI viruses came the
use of monocyte-derived macrophages (MDM) in HIV-1 infection
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experiments. Since viral pathogenesis is intimately tied to the tar-
get cells that support viral replication, efforts were made to identify
the targets of NSI HIV-1. Given that these variants replicated poorly
in transformed T cell lines,14,19 myeloid lineage cells were identified
as possible targets. In humans, some myeloid cells (monocytes and
macrophages) have been shown to express CD4,20 but at amuch lower
density than that found onCD4+T cells.21 WhenNSI viruseswere cul-
tured on MDM, many were found to replicate suggesting that these
isolates were macrophage-tropic22,23; however, they varied widely in
how well they replicated.22 Thus, the two types of HIV-1 were further
definedasSI/T cell-tropic andNSI/M-tropic.While this servedas a con-
venient designation, it was an oversimplification that ignored the fact
that NSI viruses replicatedwell in PBMCs (which generally do not con-
tainmacrophages) anddidnot always grow inMDM.However, the con-
cept of two types ofHIV-1wasquickly accepted as dogmaandanyphe-
notype not associated with SI viruses was attributed to M-tropic HIV-
1. This designation thatmost ofHIV-1wasM-tropic helped fit the virus
into another (erroneous) paradigm that the entire genus of lentiviruses
in the retrovirus family was based on macrophage tropism, a (false)
“truism” that many of us parroted for too long.
Given that CD4+ T cell lines express CD4 but do not support infec-
tion of all HIV-1 variants, this led some to reason that these cell lines
were lacking something most HIV-1 isolates needed. This conclusion
was confirmed by studies showing that HIV-1 cannot fuse with non-
human cells expressing CD4,24–28 but can fuse with human/animal
cell hybrids that express CD4.25 These findings indicated that HIV-1
requires a coreceptor (cofactor) expressed on human cells. Further-
more, this coreceptormight be cell-type specific, with one type of HIV-
1 (SI/T cell-tropic) using the coreceptor on CD4+ T cell lines and the
other type of HIV-1 (NSI/M-tropic) using a different coreceptor found
on MDM. Since PBMCs supported replication of all viruses both core-
ceptors must be present in this mixed population of cells.
An important advance came with the cloning of HIV-1 coreceptor
genes and their use in in vitro assays to show that bothCD4and a core-
ceptor are necessary to facilitate HIV-1 entry. It was first shown that
an SI variant of HIV-1 could enter nonhuman cells expressing CXCR4
and CD4, and that antibodies to CXCR4 blocked this process.29 This
identified CXCR4 as one of the elusive HIV-1 coreceptors.29 CXCR4
is a member of the large superfamily of G-protein-coupled receptors
(GPCRs)30 and is expressed on many transformed CD4+ T cell lines.18
In this way, CXCR4 became the coreceptor for the SI/T cell-tropic
viruses, later named X4 viruses. CCR5, another GPCR, was soon iden-
tified as the coreceptor for NSI/M-tropic HIV-1,31–35 later named R5
viruses. The additionof coreceptors as part of the entry phenotypewas
shoehorned into the dogmatic view of two types of HIV-1, which were
subsequently defined as X4 T cell-tropic and R5M-tropic. However, in
the sameway the termT cell-tropicwas too simplistically applied to X4
viruses; M-tropic has been too simplistically applied to R5 viruses.
1.2 Course correction: HIV-1 can be R5 T cell-tropic,
X4 T cell-tropic, or (R5) macrophage-tropic
There were several inconsistencies that had to be ignored in the “two
types” simplification of HIV-1 entry phenotypes. First, all viruses grow
in PBMCs (which contain CD4+ T cells, but not macrophages), so
why are some HIV-1 variants “T cell-tropic” and others not? Second,
not all NSI viruses grow well in macrophages (in fact most do not22),
so why are they collectively called by a single name? Third, a sub-
set of viruses, often linked to HIV-associated dementia and present
in the brain, could use a low density of CD4 much more efficiently
than the typical R5 virus.36–41 This low CD4 density is similar to that
present on macrophages.21 And fourth, most HIV-1 isolates, including
virtually all transmitted HIV-1 isolates (reviewed in Ref. 42), are not
efficient at entering MDM or other cells with a low CD4 density,
making the M-tropic designation for all R5 viruses a poor fit and
leaving the “two types” designation painfully inadequate for most
HIV-1 isolates.
In the last few years, several technical advances have yielded
enough data to crystallize a more accurate understanding of HIV-1
entry phenotypes (and therefore target cells). These advances have
allowed us to resolve inconsistencies in our understanding of entry
phenotypes and to reveal that rather than two types, there are in fact
three types ofHIV-1: (1) R5 T cell-tropic, (2) X4 T cell-tropic, and (3)M-
tropic. The X4 T cell-tropic viruses are unchanged, but the former M-
tropic classification is split, moving most HIV-1 isolates into the R5 T
cell-tropic group since M-tropic viruses are actually rare. Here we will
discuss the technical advances and theevidence theyproduced that led
to this new understanding of HIV-1 entry phenotypes.
When clones, and then inhibitors, of the two coreceptors became
available it was possible to assess entry phenotypes with respect
to coreceptor usage in a straightforward way. In contrast, assessing
macrophage tropism was/is more difficult. Entry into macrophages
uses CD4 (at a low density) and typically CCR5, just like entry into real
CD4+ T cells, begging the question, what separates M-tropic HIV-1
from R5 T cell-tropic HIV-1? Most of us have two legs as does Usain
Bolt (the world record holder at 100 and 200 m distances). Most of
us can use our legs to cover 100 m as can Usain Bolt. However, most
of us are not world class sprinters. Calling all R5 viruses M-tropic is
equivalent to saying we are all world-class sprinters because we can
cover 100m.RealM-tropic viruses are noticeably better at getting into
macrophages compared to R5 T cell-tropic viruses even though all R5
viruses can enter macrophages at least a little bit. Real macrophage-
tropic viruses are world class at using a low density of CD4 to mediate
entry, while all of the other R5 viruses are relatively pathetic at enter-
ingmacrophages or using a lowdensity ofCD4 for entry. Further, in our
own work we have generated a large panel of env genes representing
viruses from many different people to come to the conclusion that M-
tropic viruses are both exceptional in their ability to use low densities
of CD4 and rare.
The use of single genome amplification (SGA, or template end-
point dilution PCR) to amplify and clone full-length HIV-1 env genes
from patient samples without PCR recombination43–47 was essential
in generating biologically relavant env clones for analyses of entry
phenotypes. In contrast, many early studies of HIV-1 tropism used
viral isolates that were generated by culturing patient samples with
PBMCs and/or cell lines. As a result, these early studies did not exam-
ine a random sample of variants from each patient, but rather exam-
ined the tropism of viruses that were able to grow in these cells
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(typically CXCR4-using if grown on T cell lines or with artificially
reduced population complexity when passaged in PBMCs). In addition,
the culturing process used in these early studies may have allowed
viruses to adapt to culture conditions which could have altered their
entry phenotype. In contrast, the SGA method generates full-length
env clones that represent randomly chosen env genes from the viral
population within a person (without passage in culture) that can be
used in entry assays to assess tropism. This approach also avoids the
artifact of PCR-mediated recombination, which scrambles the differ-
ent lineages within a population to create genomes that never existed
in vivo. There are now hundreds of env clones available that were gen-
erated by SGA performed using patient samples collected from differ-
ent stages of disease and from different anatomical sites.
Another advancement that improved entry phenotype assessment
was the introduction of Affinofile cells.48 While one can study entry
phenotypes in MDM there is variability in the process of differ-
entiation of MDM in culture (affecting either their CD4 levels or
some feature of their intrinsic infectability) that makes it difficult
to classify alternative entry phenotypes easily and reproducibly. In
contrast, Affinofile cells have both CD4 and CCR5 under the control
of inducible promoters where the induction of each is titratable from
a low constitutive level of expression to a maximal level of expression.
At its uninduced level, the average density of CD4 on Affinofile cells
is just a little lower than that found on MDM; conversely, the fully
induced level is much higher and approaches the density found on
CD4+ T cells (Fig. 1A and Ref. 21). At their extremes, HIV-1 isolates
can have one of two CD4 usage phenotypes: All isolates maximally
infect at high CD4 levels (Figs. 1B–D), but one group retains relatively
efficient infectivity at low CD4 levels (Fig. 1D, 15–40% of the level
at high CD4) while the second group barely infects at low CD4 levels
(Figs. 1B and C, 1–2%).21,49,50 When pooling data from multiple env
clones and multiple MDM preparations we can make a rough estimate
that the first group of viruses (M-tropic viruses) is about 30-fold more
efficient at infecting MDM,49 that is the world-class M-tropic entry
phenotype. Thus we argue that using this “low-CD4” entry phenotype
as a surrogate we can identify viruses that in vivo have evolved to
infect cells with a low density of CD4, a phenotype we associate with
the infection of macrophages, making these low-CD4 viruses the
true M-tropic variants. There may be other evolutionary events that
enhance viral replication inmacrophages, but if they occur they should
be linked on a genome that encodes a low-CD4 Env protein. The
insight revealed by these studies is that coreceptor usage (X4 vs. R5)
and cellular tropism (T cells vs. macrophages) are not uniquely linked,
and therefore HIV-1 variants can be T cell-tropic and use either CCR5
(Fig. 1B) or CXCR4 (Fig. 1C). However, all X4 variants we have found in
patient samples require a high level of CD4 for efficient entry making
their designation as X4 T cell-tropic appropriate (M. Bednar and R.
Swanstrom, in preparation). In addition, whenM-tropic variants evolve
to be able to use CD4 more efficiently they do not lose the ability
to infect T cells with a high density of CD4. Perhaps we should call
M-tropic viruses M/T-tropic, but we feel the emphasis on macrophage
tropism ismore descriptive of the dramatic evolutionary step the virus
has experienced.
1.3 When andwhere to findM-tropic HIV-1
As we have used the Affinofile cell line to reevaluate entry phenotype,
we have been able to ask when and where one can find true M-tropic
viruses. M-tropic viruses are most reliably found in the CSF of people
with HIV-associated dementia (HAD) (Ref. 50 and Joseph and Kincer,
unpublished data), an AIDS-defining illness typically presenting in
subjects with advanced infection and low CD4+ T cell counts.51
These M-tropic variants are rarely observed in the blood.5,52 This
story can be extended by noting that M-tropic viruses in the CSF
represent an evolutionarily distinct lineage from the virus found
contemporaneously in the blood suggesting isolated replication in
the CNS compartment for a period of perhaps several years.50 Also,
even with M-tropic virus in the CSF, viruses in the blood are almost
exclusively T cell-tropic (either X4 or R5).21,50 Finally, when people
with M-tropic virus in their CSF go on therapy there is the expected
rapid drop of the R5 T cell-tropic virus in the blood but a slow drop
of the M-tropic virus in the CSF, indicating that the virus in the CSF
is being produced from a long-lived cell distinct from the CD4+ T
cells producing virus in the blood.50,53 Interestingly, a recent study of
HIV-1 infection in a mouse model with human myeloid lineage cells,
but lacking human T cells, found that antiretroviral therapy rapidly
lowered the blood viral load, suggesting that in this model HIV-1 may
be infecting short-lived macrophages.54 Given that M-tropic variants
aremost often found in theCSF, it isworth noting that studying virus in
the CSF is an imperfect surrogate for studying viral replication within
the CNS, a problem similar to studying virus in the blood when most
replication is occurring in lymphoid tissue. However, CSF, like blood
versus lymphoid tissue, is amore accessible sourcewherewe can learn
some things but not everything about HIV-1 in the CNS.
There are many features of the CNS compartment that are poorly
understood in the context of HIV-1 infection, but we can identify at
least two distinct phenomena involving HIV-1 production/replication
in the CNS. We often find R5 T cell-tropic viruses in the CSF that are
genetically similar to virus in the blood (i.e., equilibrated),50,53,55,56 a
phenomenon that we assume is the result of infected CD4+ T cells
translocating from the blood into the CSF/CNS and releasing virus
(with or without transient local amplification of this population). This
phenomenon is often exacerbated with pleocytosis where there is
a greater influx of cells from the blood into the CNS compartment
raising the CSF viral load but with virus that is again similar to the
virus in the blood.56 Second, it is possible to find M-tropic virus in
the CSF50,55; their frequency appears to increases with decreasing
CD4+ T cell counts in the blood (Joseph and Kincer, unpublished
data). We do not know if their presence predicts future neurocogni-
tive decline, although they are most frequently detected in the CSF
of people late in infection, especially in people with HIV-associated
dementia.36–41,50 Taken together, we envision a model where viral
replication within the CNS is limited in an immunocompetent person,
but with virus always present due to the trafficking of CD4+ T cells,
some of which are infected. At some point, the presence of virus con-
tinuously released from trafficking CD4+ T cells allows viral replica-
tion to gain a foothold in the CNS. Owing to the relative paucity of
CD4+ T cells in this compartment, there is strong selective pressure
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F IGURE 1 M-tropic HIV-1 is efficient at entering cells that express lowCD4 densities. (A) Affinofile cells48 can be induced to express different
CD4 densities, similar to the high level expressed on CD4+ T cells or the low levels expressed on MDM and monocytes. This reagent was used to
examine the ability of Env proteins to facilitate entry into cells expressing lowCD4 relative to their ability to infect high CD4 cells.21 This approach
revealed that both CXCR4-using T cell-tropic variants (B) and CCR5-using T cell-tropic variants (C) are inefficient at entering cells expressing
low levels of CD4 and require high CD4 levels (like those on T cells) for efficient entry. (D) In contrast, M-tropic Env proteins are able to effi-
ciently enter cells expressing low CD4 levels, similar to those found on macrophage, while still being able to infect cells with a high density of CD4
efficiently
to adapt to the local CNS cells that express CD4 (i.e., macrophages
and/or resident microglial cells), even if they express a low density
of CD4. This is the adaptation we measure as the ability of these
viral Env proteins to mediate entry into cells with a low density of
CD4. Thus the presence of M-tropic viruses as a distinct genetic
lineage in the CNS compartment tells us about the target cell composi-
tion in that compartment.
If the evolution of the M-tropic entry phenotype is the result of
a lack of CD4+ T cell targets then this leads to two obvious ques-
tions. First, are there other circumstances outside of the CNS where
the absence of CD4+ T cells leads to the evolution of these variants?
An early observation was that infection of macaques with an SIV/HIV
chimera (SHIV) with an HIV-1 X4-using env gene could lead to a virtu-
ally complete loss of CD4+ T cells yet maintain high viral load; when
tissue was analyzed, it was clear that there was extensive infection of
macrophages.57 Similarly, when macaques were infected after CD4+
T cell depletion there was a high level of infection now focused in
macrophages.58 Although these viruses have not been assessed for a
lowCD4 entry phenotype, it is clear that one can see a shift from infec-
tion of T cells to macrophages as the CD4+ T cell targets are depleted.
Using this logic, we examined the virus in the blood of peoplewith very
lowCD4+T cell counts.While lowCD4+T cell counts in the bloodmay
underestimate the total number of CD4+ T cells in tissue, it is indica-
tive of an immunodeficient state that is typically associated with end-
stage disease. Even in these subjects, we failed to findM-tropic viruses
in the blood although X4 viruses were common, consistent with selec-
tive pressure for alternative cell types (M. Bednar and R. Swanstrom,
in preparation). However, we did see examples of viruses with inter-
mediate M-tropic phenotypes in the blood of these severely immuno-
suppressed people, not the extremes we have observed in the CSF but
with greater ability to infect cellswith lowCD4density than is typically
seen for virus in the blood (M. Bednar and R. Swanstrom, in prepara-
tion). Thus it appears that as CD4+ T cells are lost systemically in the
human infection the virus starts to be exposed to sufficient selective
pressure to begin themove toward becomingM-tropic.
Given the difficulty in finding true M-tropic viruses, it is worth
noting several more examples of their detection. The isolation of
macrophage-tropic virus from the blood has been described,59,60
although the method of phenotyping the virus did not use Affinofile
cells. We have found a single example (to date) of a lineage of virus
in the blood that had a CD4-low entry phenotype50; in this one exam-
ple. we were able to sample virus before and shortly after the person
started therapy and found that both the standard CD4-high (T cell-
tropic) and the unexpected CD4-low (M-tropic) viruses were reduced
equivalently in blood viral load by therapy, indicating both were repli-
cating in short-lived T cells (Joseph and Swanstrom, unpublished data).
Similarly, we have detectedM-tropic virus in the semen of one male.61
We hypothesize that in each of these cases theM-tropic virus evolved
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in an isolated tissue depleted of CD4+ T cells and was introduced into
the systemic pool of replicating virus in the former or into draining
seminal fluid in the latter.
This brings us to the secondquestion:WhynotbeanM-tropic/CD4-
low virus all of the time? Why bother maintaining the CD4-high entry
phenotype? The question of why a CD4-high entry phenotype exists,
and dominates, over the CD4-low phenotype is a difficult one, which
means we do not have a clear answer. In an attempt to find phe-
notypic correlates of macrophage tropism, we noted that there is a
trend toward these viruses being more sensitive to CD4-binding site
antibodies.49 It is possible that to become more efficient in using
CD4 the virus must assume an alternative conformation making it
more susceptible to antibody neutralization. This alternative confor-
mation appears to be distinct from the “open” conformation that
one obtains with tissue culture adaptation of HIV-1. Tissue culture-
adapted virus is an artifact that has confounded and likely will con-
tinue to confound some studies of the Env protein. Tissue culture envi-
ronments lack the selective pressures present in vivo, thus allowing
Env proteins to evolve a conformation that approximates the CD4-
bound conformation, with both the V3 loop exposed and the CD4-
induced epitope formed,62,63 although these viruses still require CD4
for entry. Mutations associated with generating this open conforma-
tion are likely going to be distinct from and irrelevant to the path-
way the virus follows to become M-tropic in vivo even though both
types of viruses are able to use CD4more efficiently.64 This is because
while the M-tropic Env protein can mediate entry at a low density
of CD4 it does not display either the V3 loop or the CD4-induced
epitope.49 Thus in the same way we have to think about three types
of HIV-1 entry phenotypes (R5 T cell-tropic, X4 T cell-tropic, M-
tropic), we must think about three conformations of the Env pro-
tein: closed conformation of CD4-high Env, mostly closed conforma-
tion CD4-low Env, open conformation of tissue culture-adapted Env,
with only the closed (andmostly closed) conformations being observed
in vivo.
The maintenance of a mostly closed conformation while evolving
a CD4-low entry phenotype suggests that the presence of antibod-
ies like anti-V3 antibodies could select against the open conforma-
tion. Although the level of antibodies in the CSF is reduced relative to
plasma, it is typically only 2% that of the plasma, it may still provide
sufficient selective pressure against the virus adopting an open con-
formation. An alternative scenario for why there is selective pressure
against a CD4-low phenotype when CD4+ T cells are abundant is that
anytime the virus enters a macrophage its replication is slowed, and it
gets outcompeted by the viruses that enter CD4+T cells, making entry
intomacrophage an evolutionary disadvantage when CD4+ T cells are
around. Further, M-tropism must be positively selected for multiple
generations to become common in the population, which is unlikely
in most tissues where CD4+ T cells are in excess over macrophages
and any virus infecting a macrophage is more likely to infect a T cell
upon exiting the macrophage. Conversely, consistent positive selec-
tion for CD4-low/M tropism may be possible late in disease when
CD4+ T cells are depleted, or in environments/compartments where
the number of CD4+ T cells is low (e.g., the CNS) and a virus bud-
ding fromonemacrophagehas ahigher probability of infecting another
macrophage than a CD4+ T cell. The two explanations are not mutu-
ally exclusive, that is the same immunodeficiency that reduces target
CD4+ T cells could also cause a waning of the neutralizing antibody
response that selects against the altered conformationofmacrophage-
tropic viruses.
1.4 Exploring the preferences of T cell-tropic
viruses
HIV-1 infection of T cells has long been thought of as infection of
CD4+/CCR5+ cells early in disease and infection of CD4+/CXCR4+
cells late in disease, but it is now appreciated to be more complicated.
After completingdevelopment, naiveCD4+Tcells exit the thymusand,
if stimulated by exposure to their cognate antigen, may become acti-
vated, acquire effector functions and undergo proliferation. While the
majority of these effector cells will die, a subset will develop a mem-
ory phenotype. A distinguishing feature of naive and memory CD4+ T
cells is that naive cells expressCXCR4,whereasmemoryTcells express
both CXCR4 and CCR5.20 As we noted above, virtually all transmitted
HIV-1 and the vast majority of HIV-1 variants in the blood throughout
infection are adapted to using CCR5 and not CXCR4 (reviewed in Ref.
42).While these observationswould suggest thatmostHIV-1 is unable
to infect naiveCD4+T cells, viral DNAcan often be found in both naive
and memory T cells isolated from the blood of untreated people from
different stages of infection.65 It is currently unclear whether these
naive cells are exclusively infected by CXCR4-using variants (which
are typically rare until late in disease) or may occasionally represent
aberrant infection of naive cells by CCR5-using variants. The potential
low-level use of CXCR4 by R5 viruses would provide an evolutionary
mechanism for the coreceptor switch fromCXCR4toCCR5.Why there
is a coreceptor switch remains an interesting question. It may hap-
pen as the result of depletion of CD4+ memory T cells which express
CXCR4+/CCR5+, making the virus more likely to encounter a naive
cell that expresses CXCR4, but not CCR5. Alternatively, infection of
largely quiescent naive cells may represent its own form of inefficient
replication, such that virus in this cell population is at a disadvantage
in terms of time to virus release or burst size relative to virus in acti-
vated T cells. This may explain why the X4 phenotype is more common
late in disease when the favored target cells are relatively depleted,
and perhaps immunosurveillance of poorly replicating viral reservoirs
is decreased.
The ability of HIV-1 to primarily infect CD4+ memory T cells, but
also infect naive cells is further supported by recent studies of viral
reservoirs. Studies examining intact proviral genomes66 and quanti-
tative viral outgrowth assays (QVOA)67 have found that HIV-1 can
persist in naive and memory CD4+ T cells in ART-treated individu-
als regardless of whether individuals initiate therapy during acute or
chronic infection. However, it is worth noting that the percentage of
naive cells harboring replication-competent proviral genomes is typi-
cally lower than that of memory T cells.66,67 The fact that naive cells
are less likely tobe latently infectedafter aperiodofARTmaybedue to
thembeing less susceptible to infection prior to therapy or due to them
turning over more rapidly after the initiation of therapy. An additional
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factor that may reduce the number of latently infected naive cells is
that over time theymight develop amemory phenotype.
While memory CD4+ T cells are generally accepted as the largest
reservoir of replication-competent proviruses during ART, we are only
beginning to understand the contribution that different memory sub-
setsmake to the reservoir and theprocessesmaintaining these latently
infected cells. Memory cells can be divided into a variety of subsets
including stem cell (TSCM), transitional (TTM), central (TCM), effector
(TEM), and terminal effector (TTE) memory cells, all of which differ in
many ways including their homing68 and effector functions.68 Multi-
ple studies have identified TCM as the primary reservoir of latent HIV-
1 during ART (Refs. 67,69, but also see Ref. 66). However, the contri-
bution that different memory subsets make to the reservoir may vary
based on the degree of CD4+ T cell depletion in subjects on ART, with
lower CD4+ T cell counts being associated with a higher frequency
of infected TTM and TEM cells and a lower frequency of infected TCM
cells.69 These changes are likely driven by overall depletion of mem-
ory cells and homeostatic proliferation of HIV-infected TTM.
69 The sig-
nificance of T cell proliferation in the maintenance of the viral reser-
voir is further supported by analyses of proviral integration sites,70–72
sequencing of low-level viral RNA in the plasma during ART,73 and
sequencing of virus produced during QVOA.74
While cellular proliferationmay expand some viral lineages, there is
little evidence of viral replication during ART based on analyses of viral
sequences in the blood (Refs. 75,76). A possible exception to this is in
lymphnode follicleswhere poor penetration ofARTdrugs78 andCD8+
T cells79 may facilitate HIV-1 replication in CD4+ follicular helper T
(TFH) cells despite therapy.
77,78 Whether or not there is active replica-
tion during ART, it is clear that rebound virus quickly appears in lymph
nodes with therapy discontinuation.80
1.5 HIV-1 and the latent reservoir
One of the truisms of HIV-1 therapy is that when therapy is stopped
the virus comes back, thus necessitating the need for life-long treat-
ment. The main culprit for the source of this rebound virus is gener-
ally thought to be resting CD4+ T cells that contain latent copies of
integrated viral DNA that can be induced to produce virus.81–83 When
we examined the entry phenotype of the rebound virus that initially
appears in the plasma of people stopping therapy, we found it was
R5 T cell-tropic.84 This is consistent with a T cell reservoir, and most
efforts directed at curing HIV-1 are focused on this cell type. Yet there
is significant interest in knowing if there could be a separate latent
reservoir in macrophages, either in the periphery or in the CNS. One
can imagine a large reservoir of virus in T cells and a smaller reser-
voir in macrophages. Eradication of virus from T cells would be inad-
equate for a cure in this case. While we have argued that the major
form of HIV-1 should be considered R5 T cell-tropic, even this form of
the virus can inefficiently infect macrophages with their low density of
CD4. Given an entire body, there must be many macrophages that get
infected fortuitously by R5 T cell-tropic virus. Thus the potential for a
macrophage reservoir, even in the absence of detectingM-tropic virus,
must exist. A first step in addressing this questionhas beenmadewith a
humanizedmousemodel systemwith onlymyeloid-derived target cells
present to supportHIV-1 replication. In this system, the virus persisted
for several weeks while the mice were given antiretroviral therapy fol-
lowed by reboundwhen therapy was stopped.54 This striking observa-
tion reminds us that the interaction between HIV-1 and its target cell
will continue to challenge us as we further move our understanding of
replication and persistence from the cell culture setting to all that is
happening within an infected person.
1.6 Shouting down echoes of the past
This characterization of three types of HIV-1, with R5 T cell-tropic
being the most abundant, is supported by compelling evidence. We
can anticipate refinements of any construct with future information,
but this framework accounts for much more of the biology of HIV-1
than does the longstanding “two types” categorization. However, the
drag of 20+ years of self-reinforced dogma will continue to confound
the thinking in our field. As one example (there are many), we can
cite our much beloved Principles of Virology (4th ed., 2015) that stops
with the description of “X4 and R5 strains,” makes a vague reference
to “strains with enhanced neurotropism,” and describes the late stage
virus in the blood as becoming “relatively homogeneous and specific
for the CXCR4 receptor. Properties associated with increased viru-
lence predominate, including an expanded cellular host range, ability
of the virus to cause formation of syncytia, rapid reproduction kinet-
ics, and CD4+ T cell cytopathogenicity” (pp. 230–236). These are the
remaining echoes of the early use of CD4+ T cell lines expressing only
CD4 and CXCR4. For example, when one looks at the population of
virus in the blood within a person with low levels of CD4 (using deep
sequencing) some people have no X4 virus, a few people have all X4
virus, but for most people with X4 virus it represents a minor lineage
with the R5 T cell-tropic virus still predominating. In Fig. 2, we include
an example of such an analysis taken from Zhou et al. showing the per-
sistence of R5 viruses at high levels in the blood even when X4 viruses
are present85 (although we do not know what the ratio of these vari-
ants might be in tissues or how much different tissues contribute to
plasma viremia). Themore accurate characterization of the three entry
phenotypes of HIV-1 puts R5 T cell-tropic viruses at the center of
the HIV-1 story, gives a better definition beyond “neurotropic” to the
types of viruses that are found in the CNS, explains why theymay have
evolved there, and places both X4 T cell-tropic viruses and M-tropic
viruses as usually minor evolutionary variants that are rarely transmit-
ted and appear when CD4+/CCR5+ T cells are depleted.
2 SUMMARY
There are three types of HIV-1 not two: R5 T cell-tropic (the stan-
dard virus), andX4T cell-tropic andM-tropic (the latter two evolved to
either use anewcoreceptor or to infectmoreefficiently cellswith a low
level of CD4). The analysis of genetic compartmentalization and differ-
ing entry phenotypes provides insights into local tissue environments
where viral replication can occur. It is important to correctly under-
stand the biology of the virus to be able to interpret its interactionwith
the host.
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F IGURE 2 Viral populations present in the blood late in disease. Plasma samples from subjects with low CD4+ T cell counts (“late-stage sub-
jects”) were used as the source of viral RNA for deep sequencing of the C2 to V3 region of the viral env gene. Phylogenetic trees show the diver-
sity of the viral population in each subject. The lineages are color coded based on the false positive rate (FPR) of predicting X4 lineages using the
Geno2Pheno algorithm. We found that all lineages with values above 10% were R5 viruses phenotypically (blue and green), lineages with values
less than 2%were X4 (red), and lineageswith FPR values between 2% and 10% (orange and blue) were R5 75%of the time. For comparison, a group
of three “early-stage subjects” are included showing limited diversity associated with the transmission of a single variant and R5-predicted phe-
notypes. Taken from Zhou et al.85 with permission. Copyright c© American Society for Microbiology, Journal of Virology, 90:7142–7158, 2016. doi:
10.1128/JVI.00441-16
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